Boehringer collaborates with Havard
pharmafile | July 9, 2012 | News story | Research and Development, Sales and Marketing | Boehringer, Havard, oncology, research deal
Boehringer Ingelheim has established a translational research collaboration with the presidents and fellows of Harvard College.
The aim of the collaboration is for Boehringer to work together with the scientific community of Harvard in order to advance knowledge in areas of high unmet medical need.
Dr Adrian Carter, corporate VP of Global Research Networking at Boehringer said: “We are very pleased to sponsor the joint research programs by the distinguished scientists at Harvard in these important fields of medical need”.
The focus of the different research projects is to identify and investigate novel signalling pathways and drug targets in oncology, cardiometabolic, fibrotic and infectious diseases.
Terms of the agreement show the collaboration will sponsor a variety of research projects by awarding funds to support proposals selected by a joint research committee, comprised of representatives from the Harvard Medical School ICCB-Longwood Screening Facility, various Harvard Affiliated Institutions and Boehringer.
The funding will also enable the Harvard research community to address several RNAi screening projects using specifically tailored screening systems.
To date, the collaboration has selected and supported eight projects of scientific and educational value in the areas of cancer stem cell survival, replication of detrimental viruses and fibrotic processes.
Carter added: “We believe that this research collaboration with Harvard will help us create new medicines for a variety of important diseases that afflict our society today.”
Brett Wells
Related Content
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
